Aldosterone synthase gene CYPIIB2 -344C/T polymorphism and gender aspects of antihypertensive treatment efficacy

Abstract

Background. There is growing evidence that high interindividual variability in response to blood-lowering medications is partially explained by genetic factors. Multiple genes, encoding blood pressure-regulating drug receptors and receptor response mechanisms are Associated with different results in achieving target BP values under antihypertensive treatment. Despite some consistent research, showing that various genetic single-nucleotide polymorphisms (SNP) may affect antihypertensive treatment efficacy, study results in this field continue to be conflicting and provide disparate results [1]. Aldosterone is the key mineralocorticoid rennin-angiotensin-aldosteron system (RAAS) hormone, affecting distal nephron to regulate sodium resorption, excretion of potassium, and intravascular volume. So the associations between aldosterone synthase gene polymorphism and hypertension would thus be of significant interest. Studies about the potential role of aldosterone synthase gene CYP11B2 (-344T/C) polymorphism and primary hypertension demonstrated controversial results. Some results indicate that -344T/C polymorphism has an impact on hypertensive target organ damage and the response to antihypertensive drugs [2  4]. For YP11B2 ( -e3x4a4mTp/Cle), gsetundei es have polymorphism is Associated with the antihypertensive response to diuretics and RAAS-inhibitors [5 7]. Due to small study samples and controversial results, even in conditions of one population, it remains unclear, whether CYP11B2 -344T/C single-nucleotide polymorphism (SNP) affects antihypertensive treatment response and long-term treatment outcomes. Gender-related aspects of hypertension is a research field based on physiological tendency of men to have higher BP values during the whole lifespan, regardless of race or ethnicity. Men also tend to have more modifiable risk factors, such as excessive alcohol consumption, smoking, poor diet, sedentary lifestyle, etc. [8] Highlighting mechanisms, underlying sex differences in hypertension may lead to development of tailored therapeutic strategies, adaptive to specific gender-related variables, thus improving treatment outcomes [9 10].